Expert Interview
Discussing the appropriate use and future of Pluvicto Radionuclide Therapy amidst the developing treatment landscape for genitourinary cancers.
Ticker(s): NVS, FUSN, RYZB, PNTInstitution: University of Minnesota (formerly Hopkins)
- Associate Director for Translational Research at the Masonic Cancer Center & Director of Genitourinary Oncology Hematology, Oncology, and Transplantation) at the University of Minnesota Medical School.
- Clinical interest is the management of prostate cancer and other genitourinary malignancies.
- Research focuses on developing novel androgen-directed therapies, genetically-targeted therapies, and immunotherapies for men with recurrent or advanced prostate cancer, and using germline and cancer genomics to inform precision oncology approaches.
Can you explain the pros and cons of specific approaches to radioligand therapies such as; using antibodies, small molecules, or other targeting moieties?
Added By: sara_adminAny thoughts on how Bristol Myers Squibb's acquisition of Rayze Bio will be impactful to the radiopharmaceutical industry?
Added By: sara_adminCan you discuss which actinium based radiotherapies in development most excite you?
Added By: sara_adminFor actinium therapies, what would be an acceptable rate of salivary gland toxicity? Would Grade 3 or higher events give you pause in using in Post-Lu patients?
Added By: mattgamberWhat would need to happen to bring Ac therapies to an earlier line setting, even before Lu therapies?
Added By: mattgamberWhere do you see the total addressable market for Lu and Ac therapies ultimately settling in at with radiopharmaceuticals receiving more uptake and awareness?
Added By: mattgamberAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
